Journal article
The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
Melita K Kenealy, John F Seymour, Cowan Linda, Alvin Milner, Pratyush Giri, Shir-Jing Ho, Warwick Benson, Andrew Nicol, Philip Campbell, Ian Prosser, Craig Underhill, Ilona Cunningham, Anthony K Mills, Jeffrey Szer, Peter Presgrave, Robin Filshie
Blood | American Society of Hematology | Published : 2009
Abstract
Abstract Abstract 1749 Poster Board I-775 Introduction Both thalidomide (Thal) and 5-azacitidine (Vidaza; AZA) have single-agent activity in patients (pts) with myelodysplastic syndromes (MDS), but there is limited experience with the combination. The addition of Thal to AZA may improve efficacy, but tolerability of the combination may be limited by side-effects. Patients and Methods This analysis included all evaluable pts on the Ph I/II Australasian Leukaemia and Lymphoma group (ALLG) MDS3 study of Thal and AZA. Pts were eligible if they had ..
View full abstract